These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

426 related items for PubMed ID: 19808131

  • 1. Long-term follow-up of the original interferon-beta1b trial in multiple sclerosis: design and lessons from a 16-year observational study.
    Ebers GC, Reder AT, Traboulsee A, Li D, Langdon D, Goodin DS, Wolf C, Beckmann K, Konieczny A, Investigators of the 16-Year Long-Term Follow-Up Study.
    Clin Ther; 2009 Aug; 31(8):1724-36. PubMed ID: 19808131
    [Abstract] [Full Text] [Related]

  • 2. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.
    Kappos L, Traboulsee A, Constantinescu C, Erälinna JP, Forrestal F, Jongen P, Pollard J, Sandberg-Wollheim M, Sindic C, Stubinski B, Uitdehaag B, Li D.
    Neurology; 2006 Sep 26; 67(6):944-53. PubMed ID: 17000959
    [Abstract] [Full Text] [Related]

  • 3. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
    Hurwitz BJ, Jeffery D, Arnason B, Bigley K, Coyle P, Goodin D, Kaba S, Kirzinger S, Lynch S, Mandler R, Mikol D, Rammohan K, Sater R, Sriram S, Thrower B, Boateng F, Jakobs P, Wash MB, Bogumil T.
    Clin Ther; 2008 Jun 26; 30(6):1102-12. PubMed ID: 18640466
    [Abstract] [Full Text] [Related]

  • 4. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.
    Togha M, Karvigh SA, Nabavi M, Moghadam NB, Harirchian MH, Sahraian MA, Enzevaei A, Nourian A, Ghanaati H, Firouznia K, Jannati A, Shekiba M.
    Mult Scler; 2010 Jul 26; 16(7):848-54. PubMed ID: 20488825
    [Abstract] [Full Text] [Related]

  • 5. Interferon-beta1b in multiple sclerosis: effect on progression of disability and clinical markers of treatment response.
    Carmona O, Casado V, Moral E, Alonso-Magdalena L, Martínez-Yélamos A, Martínez-Yélamos S, Martín-Ozaeta G, Arbizu T.
    Eur Neurol; 2008 Jul 26; 60(6):279-84. PubMed ID: 18824855
    [Abstract] [Full Text] [Related]

  • 6. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
    Schwid SR, Panitch HS.
    Clin Ther; 2007 Sep 26; 29(9):2031-48. PubMed ID: 18035202
    [Abstract] [Full Text] [Related]

  • 7. PRISMS: the story of a pivotal clinical trial series in multiple sclerosis.
    Cohen BA, Rivera VM.
    Curr Med Res Opin; 2010 Apr 26; 26(4):827-38. PubMed ID: 20121658
    [Abstract] [Full Text] [Related]

  • 8. Intramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis: a 15-year follow-up study.
    Bermel RA, Weinstock-Guttman B, Bourdette D, Foulds P, You X, Rudick RA.
    Mult Scler; 2010 May 26; 16(5):588-96. PubMed ID: 20167591
    [Abstract] [Full Text] [Related]

  • 9. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ.
    Clin Ther; 2006 Apr 26; 28(4):461-74. PubMed ID: 16750460
    [Abstract] [Full Text] [Related]

  • 10. [Clinical assessment of the course of relapsing-remitting multiple sclerosis in patients treated with interferon beta].
    Pokryszko-Dragan A, Bilińska M, Gruszka E, Dubik-Jezierzańska M.
    Pol Merkur Lekarski; 2005 Nov 26; 19(113):654-8. PubMed ID: 16498805
    [Abstract] [Full Text] [Related]

  • 11. High-dose, frequently administered interferon beta therapy for relapsing-remitting multiple sclerosis must be maintained over the long term: the interferon beta dose-reduction study.
    Barbero P, Verdun E, Bergui M, Pipieri A, Clerico M, Cucci A, Ricci A, Bergamasco B, Durelli L.
    J Neurol Sci; 2004 Jul 15; 222(1-2):13-9. PubMed ID: 15240190
    [Abstract] [Full Text] [Related]

  • 12. Effects of interferon beta-1a and -1b over time: 6-year results of an observational head-to-head study.
    Patti F, Pappalardo A, Florio C, Politi G, Fiorilla T, Reggio E, Reggio A.
    Acta Neurol Scand; 2006 Apr 15; 113(4):241-7. PubMed ID: 16542163
    [Abstract] [Full Text] [Related]

  • 13. Safety and tolerability in relapsing-remitting multiple sclerosis patients treated with high-dose subcutaneous interferon-beta by Rebiject autoinjection over a 1-year period: the CoSa study.
    Lugaresi A, Durastanti V, Gasperini C, Lai M, Pozzilli C, Orefice G, Sotgiu S, Pucci E, Ardito B, Millefiorini E, CoSa Study Group.
    Clin Neuropharmacol; 2008 Apr 15; 31(3):167-72. PubMed ID: 18520983
    [Abstract] [Full Text] [Related]

  • 14. Defining interferon beta response status in multiple sclerosis patients.
    Rudick RA, Lee JC, Simon J, Ransohoff RM, Fisher E.
    Ann Neurol; 2004 Oct 15; 56(4):548-55. PubMed ID: 15389896
    [Abstract] [Full Text] [Related]

  • 15. Interferon beta-1b is effective in Japanese RRMS patients: a randomized, multicenter study.
    Saida T, Tashiro K, Itoyama Y, Sato T, Ohashi Y, Zhao Z, Interferon Beta-1b Multiple Sclerosis Study Group of Japan.
    Neurology; 2005 Feb 22; 64(4):621-30. PubMed ID: 15728282
    [Abstract] [Full Text] [Related]

  • 16. A reassessment of the plateauing relationship between T2 lesion load and disability in MS.
    Sormani MP, Rovaris M, Comi G, Filippi M.
    Neurology; 2009 Nov 10; 73(19):1538-42. PubMed ID: 19794123
    [Abstract] [Full Text] [Related]

  • 17. Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients.
    Río J, Nos C, Tintoré M, Téllez N, Galán I, Pelayo R, Comabella M, Montalban X.
    Ann Neurol; 2006 Feb 10; 59(2):344-52. PubMed ID: 16437558
    [Abstract] [Full Text] [Related]

  • 18. Reduced effectiveness of long-term interferon-beta treatment on relapses in neutralizing antibody-positive multiple sclerosis patients: a Canadian multiple sclerosis clinic-based study.
    Boz C, Oger J, Gibbs E, Grossberg SE, Neurologists of the UBC MS Clinic.
    Mult Scler; 2007 Nov 10; 13(9):1127-37. PubMed ID: 17967840
    [Abstract] [Full Text] [Related]

  • 19. Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing-remitting MS.
    Reder AT, Ebers GC, Traboulsee A, Li D, Langdon D, Goodin DS, Bogumil T, Beckmann K, Konieczny A, Investigators of the 16-Year Long-Term Follow-Up Study.
    Neurology; 2010 Jun 08; 74(23):1877-85. PubMed ID: 20530324
    [Abstract] [Full Text] [Related]

  • 20. Rationale and design of the prospective and retrospective observational study of Avonex and Rebif (PROOF) for the treatment of relapsing-remitting multiple sclerosis.
    Murray TJ.
    Curr Med Res Opin; 2004 Jan 08; 20(1):25-30. PubMed ID: 14741068
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.